Document Detail

Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis.
MedLine Citation:
PMID:  21083514     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate the effects of timing and length of zoledronic acid (ZA) treatment on outcomes for patients with prostate cancer in clinical practice.
MATERIALS AND METHODS: Patients with prostate cancer and first bone metastasis diagnosed from January 2003 to October 2006 were included. Patients were considered 'untreated' if no ZA was given, 'early ZA-treated' if ZA was initiated before skeletal complication (SC) occurrence or 'late ZA-treated' if one or more SC was documented before or at ZA initiation. Patients were classified with short (≤ 90 days), medium (91-180 days) or long (>180 days) treatment persistence. Assessments included follow-up duration (FUP) and risk of developing one or more SC.
RESULTS: Among eligible patients, 847 were untreated, 243 were early ZA-treated and 218 were late ZA-treated. For untreated versus early ZA-treated groups, median FUP was 263 versus 357 days (p < 0.0001), respectively, and time to first SC was 199 versus 273 days (p < 0.0001), respectively. ZA treatment was associated with significantly longer FUP and lower SC risk. The early ZA-treated group had significantly longer FUP versus the late ZA-treated group (median days, 357 vs. 299.5); the late ZA-treated group experienced significantly higher SC risk vs. the early ZA-treated group (odds ratio, 1.51). Compared with the long-persistence group, FUP was 56% and 40% shorter in the short and medium groups, respectively (p < 0.0001).
CONCLUSION: Treatment with and early initiation of ZA for patients with prostate cancer and bone metastasis significantly prolonged time to and reduced risk of developing SC, while extending FUP.
Hind T Hatoum; Swu-Jane Lin; Amy Guo; Allan Lipton; Matthew R Smith
Related Documents :
11489704 - Impact of a modified apical dissection during radical retropubic prostatectomy on the o...
17919694 - Short-term health outcome differences between robotic and conventional radical prostate...
16926854 - Plasmakinetic resection of the prostate versus standard transurethral resection of the ...
17379044 - A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enl...
19818574 - Continuous positive airway pressure vs. pressure support ventilation in acute cardiogen...
24011864 - Congestive heart failure as a determinant of postoperative delirium.
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-11-18
Journal Detail:
Title:  Current medical research and opinion     Volume:  27     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-17     Completed Date:  2011-04-01     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  55-62     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Bone Density Conservation Agents / therapeutic use
Bone Diseases / epidemiology,  etiology*,  prevention & control*
Bone Neoplasms / complications*,  drug therapy*,  secondary
Cohort Studies
Diphosphonates / therapeutic use*
Follow-Up Studies
Imidazoles / therapeutic use*
Middle Aged
Prostatic Neoplasms / complications*,  drug therapy*,  pathology
Retrospective Studies
Treatment Outcome
Grant Support
K24 CA121990/CA/NCI NIH HHS; K24 CA121990-05/CA/NCI NIH HHS
Reg. No./Substance:
0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 118072-93-8/zoledronic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components.
Next Document:  Observational, nonintervention, multicenter study for validation of the Bowel Function Index for con...